Avalon GloboCare (NASDAQ:ALBT) Issues Earnings Results

Avalon GloboCare (NASDAQ:ALBT) issued its quarterly earnings results on Monday. The company reported ($0.49) earnings per share for the quarter, Zacks reports.

Avalon GloboCare Stock Performance

Shares of ALBT traded down $0.03 during trading hours on Wednesday, hitting $0.36. The stock had a trading volume of 102,821 shares, compared to its average volume of 5,045,465. The firm has a 50-day moving average price of $0.56 and a 200 day moving average price of $1.03. Avalon GloboCare has a fifty-two week low of $0.34 and a fifty-two week high of $4.74. The firm has a market capitalization of $3.00 million, a price-to-earnings ratio of -0.10 and a beta of -0.04.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare presently has an average rating of “Sell”.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.